Market Overview

Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

Share:
Related NAVB
Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages
Navidea Announces Clinical Data for Manocept Shows Agent Localizes in Multiple KS Lesions

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

Posted-In: News

 

Related Articles (NAVB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters